Polymorphism of human cytochrome P450 enzymes and its clinical impact
Pharmacogenetics is the study of how interindividual variations in the DNA sequence of
specific genes affect drug response. This article highlights current pharmacogenetic …
specific genes affect drug response. This article highlights current pharmacogenetic …
Inhibition and induction of human cytochrome P450 enzymes: current status
Variability of drug metabolism, especially that of the most important phase I enzymes or
cytochrome P450 (CYP) enzymes, is an important complicating factor in many areas of …
cytochrome P450 (CYP) enzymes, is an important complicating factor in many areas of …
Fluorine in health care: Organofluorine containing blockbuster drugs
D O'Hagan - Journal of Fluorine Chemistry, 2010 - Elsevier
Organic fluorine compounds have had a profound impact on the development of bioactives
for the modern pharmaceuticals market. It is estimated that up to 20% of pharmaceuticals …
for the modern pharmaceuticals market. It is estimated that up to 20% of pharmaceuticals …
Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics
RM Ward, GL Kearns - Pediatric Drugs, 2013 - Springer
Proton pump inhibitors (PPIs) have become some of the most frequently prescribed
medications for treatment of adults and children. Their effectiveness for treatment of peptic …
medications for treatment of adults and children. Their effectiveness for treatment of peptic …
Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development
SF Zhou, ZW Zhou, LP Yang… - Current medicinal …, 2009 - ingentaconnect.com
Cytochrome P450 2C9 (CYP2C9) is one of the most abundant CYP enzymes in the human
liver. CYP2C9 metabolizes more than 100 therapeutic drugs, including tolbutamide …
liver. CYP2C9 metabolizes more than 100 therapeutic drugs, including tolbutamide …
Acid suppression therapy: where do we go from here?
C Scarpignato, I Pelosini, F Di Mario - Digestive Diseases, 2006 - karger.com
The dramatic success of pharmacological acid suppression in healing peptic ulcers and
managing patients with gastroesophageal reflux disease (GERD) has been reflected in the …
managing patients with gastroesophageal reflux disease (GERD) has been reflected in the …
High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis …
MV Fawaz, AF Brooks, ME Rodnick… - ACS chemical …, 2014 - ACS Publications
Abnormally aggregated tau is the hallmark pathology of tauopathy neurodegenerative
disorders and is a target for development of both diagnostic tools and therapeutic strategies …
disorders and is a target for development of both diagnostic tools and therapeutic strategies …
Pharmacokinetics of proton pump inhibitors in children
C Litalien, Y Théorêt, C Faure - Clinical pharmacokinetics, 2005 - Springer
The use of proton pump inhibitors (PPIs) has become widespread in children and infants for
the management of paediatric acid-related disease. Pharmacokinetic profiles of only …
the management of paediatric acid-related disease. Pharmacokinetic profiles of only …
Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms
XS Lai, LP Yang, XT Li, JP Liu, ZW Zhou… - Current drug …, 2009 - ingentaconnect.com
Human CYP2C8 is a key member of the CYP2C family and metabolizes more than 60
clinical drugs. A number of active site residues in CYP2C8 have been identified based on …
clinical drugs. A number of active site residues in CYP2C8 have been identified based on …
Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole
F Qi, L Zhu, N Li, T Ge, G Xu, S Liao - International journal of antimicrobial …, 2017 - Elsevier
This study aimed to determine the influence of proton pump inhibitors (PPIs) on the
pharmacokinetics of voriconazole and to characterise potential drug–drug interactions …
pharmacokinetics of voriconazole and to characterise potential drug–drug interactions …